{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T09:38:51Z","timestamp":1788514731444,"version":"build-2803163510"},"reference-count":143,"publisher":"MDPI AG","issue":"3","license":[{"start":{"date-parts":[[2020,1,30]],"date-time":"2020-01-30T00:00:00Z","timestamp":1580342400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>Lymphoma, a group of widely prevalent hematological malignancies of lymphocyte origin, has become the focus of significant clinical research due to their high propensity for refractory\/relapsed (R\/R) disease, leading to poor prognostic outcomes. The complex molecular circuitry in lymphomas, especially in the aggressive phenotypes, has made it difficult to find a therapeutic option that can salvage R\/R disease. Furthermore, the association of lymphomas with the Bone Marrow (BM) microenvironment has been found to portend worse outcomes in terms of heightened chances of relapse and acquired resistance to chemotherapy. This review assesses the current therapy options in three distinct types of lymphomas: diffuse large B-cell lymphoma, follicular lymphoma and mantle cell lymphoma. It also explores the role of the BM tumor microenvironment as a secure \u2018niche\u2019 for lymphoma cells to grow, proliferate and survive. It further evaluates potential mechanisms through which the tumor cells can establish molecular connections with the BM cells to provide pro-tumor benefits, and discusses putative therapeutic strategies for disrupting the BM-lymphoma cell communication.<\/jats:p>","DOI":"10.3390\/ijms21030904","type":"journal-article","created":{"date-parts":[[2020,1,31]],"date-time":"2020-01-31T05:55:46Z","timestamp":1580450146000},"page":"904","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["Impact and Intricacies of Bone Marrow Microenvironment in B-cell Lymphomas: From Biology to Therapy"],"prefix":"10.3390","volume":"21","author":[{"given":"Anuvrat","family":"Sircar","sequence":"first","affiliation":[{"name":"Division of Hematology, Department of Internal Medicine, The Ohio State University, Columbus, OH 43210, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sayan","family":"Chowdhury","sequence":"additional","affiliation":[{"name":"Division of Hematology, Department of Internal Medicine, The Ohio State University, Columbus, OH 43210, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amber","family":"Hart","sequence":"additional","affiliation":[{"name":"Division of Hematology, Department of Internal Medicine, The Ohio State University, Columbus, OH 43210, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William","family":"Bell","sequence":"additional","affiliation":[{"name":"Division of Hematology, Department of Internal Medicine, The Ohio State University, Columbus, OH 43210, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9957-9566","authenticated-orcid":false,"given":"Satishkumar","family":"Singh","sequence":"additional","affiliation":[{"name":"Division of Hematology, Department of Internal Medicine, The Ohio State University, Columbus, OH 43210, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1151-5427","authenticated-orcid":false,"given":"Lalit","family":"Sehgal","sequence":"additional","affiliation":[{"name":"Division of Hematology, Department of Internal Medicine, The Ohio State University, Columbus, OH 43210, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8216-3457","authenticated-orcid":false,"given":"Narendranath","family":"Epperla","sequence":"additional","affiliation":[{"name":"Division of Hematology, Department of Internal Medicine, The Ohio State University, Columbus, OH 43210, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2020,1,30]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"12359","DOI":"10.18632\/oncotarget.7132","article-title":"Clonal relationships in recurrent B-cell lymphomas","volume":"7","author":"Lee","year":"2016","journal-title":"Oncotarget"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1080\/17474086.2017.1283214","article-title":"Treatment approaches of hard-to-treat non-Hodgkin lymphomas","volume":"10","author":"Nandagopal","year":"2017","journal-title":"Expert Rev. Hematol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"2375","DOI":"10.1182\/blood-2016-01-643569","article-title":"The 2016 revision of the World Health Organization classification of lymphoid neoplasms","volume":"127","author":"Swerdlow","year":"2016","journal-title":"Blood"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1038\/leu.2017.222","article-title":"Concordant bone marrow involvement of diffuse large B-cell lymphoma represents a distinct clinical and biological entity in the era of immunotherapy","volume":"32","author":"Yao","year":"2018","journal-title":"Leukemia"},{"key":"ref_5","doi-asserted-by":"crossref","unstructured":"Wang, D., Liu, P., Zhang, Y., Liu, H.-Y., Shen, D., and Che, Y.-Q. (2018). Bone Marrow Molecular Markers Associated with Relapsed\/Refractory Activated B-Cell-Like Diffuse Large B-Cell Lymphoma. Biomed Res. Int., 2018.","DOI":"10.1155\/2018\/1042597"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1093\/ajcp\/106.2.196","article-title":"Mantle cell lymphoma: Morphologic findings in bone marrow involvement","volume":"106","author":"Wasman","year":"1996","journal-title":"Am. J. Clin. Pathol."},{"key":"ref_7","first-page":"693","article-title":"Human mesenchymal stem cells isolated from bone marrow and lymphoid organs support tumor B-cell growth: Role of stromal cells in follicular lymphoma pathogenesis","volume":"109","author":"Monvoisin","year":"2006","journal-title":"Blood"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1200\/JCO.1990.8.7.1163","article-title":"Bone marrow involvement by non-Hodgkin\u2019s lymphoma: The clinical significance of morphologic discordance between the lymph node and bone marrow. Nebraska Lymphoma Study Group","volume":"8","author":"Conlan","year":"1990","journal-title":"J. Clin. Oncol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1186\/s13046-019-1081-7","article-title":"Human bone marrow-derived mesenchymal stem cells promote the growth and drug-resistance of diffuse large B-cell lymphoma by secreting IL-6 and elevating IL-17A levels","volume":"38","author":"Zhong","year":"2019","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"2519","DOI":"10.1158\/1078-0432.CCR-07-2223","article-title":"The bone marrow microenvironment as a tumor sanctuary and contributor to drug resistance","volume":"14","author":"Meads","year":"2008","journal-title":"Clin. Cancer Res."},{"key":"ref_11","first-page":"1278","article-title":"Concordant but not discordant bone marrow involvement in diffuse large B-cell lymphoma predicts a poor clinical outcome independent of the International Prognostic Index","volume":"110","author":"Chung","year":"2007","journal-title":"Blood J. Am. Soc. Hematol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1111\/j.1600-0609.2006.00644.x","article-title":"The prognostic impact of bone marrow involvement in patients with diffuse large cell lymphoma varies according to the degree of infiltration and presence of discordant marrow involvement","volume":"76","author":"Campbell","year":"2006","journal-title":"Eur. J. Haematol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1330","DOI":"10.5858\/arpa.2018-0217-RA","article-title":"Follicular lymphoma diagnostic caveats and updates","volume":"142","author":"Choi","year":"2018","journal-title":"Arch. Pathol. Lab. Med."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1159\/000101712","article-title":"Diagnosis and classification of malignant lymphoma and related entities in the bone marrow trephine biopsy","volume":"74","author":"Fend","year":"2007","journal-title":"Pathobiology"},{"key":"ref_15","doi-asserted-by":"crossref","unstructured":"Greenbaum, U., Levi, I., Madmoni, O., Lior, Y., Al-Athamen, K., Howard Perry, Z., Hatzkelzon, L., and Shubinsky, G. (2019). The prognostic significance of bone marrow involvement in diffuse large B cell lymphoma according to the flow cytometry. Leuk. Lymphoma, 1\u20136.","DOI":"10.1080\/10428194.2019.1587755"},{"key":"ref_16","first-page":"679","article-title":"Definitive salvage chemotherapy for the treatment of refractory\/relapsed non-Hodgkin lymphoma, a single center experience","volume":"54","author":"Hafez","year":"2018","journal-title":"Alex. J. Med."},{"key":"ref_17","first-page":"7","article-title":"Cancer statistics, 2019","volume":"69","author":"Siegel","year":"2019","journal-title":"Ca: A Cancer J. Clin."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"2848","DOI":"10.1200\/JCO.2014.60.2383","article-title":"Prognostic significance of diffuse large B-cell lymphoma cell of origin determined by digital gene expression in formalin-fixed paraffin-embedded tissue biopsies","volume":"33","author":"Scott","year":"2015","journal-title":"J. Clin. Oncol."},{"key":"ref_19","first-page":"2319","article-title":"Double-hit B-cell lymphomas","volume":"117","author":"Aukema","year":"2011","journal-title":"BloodJ. Am. Soc. Hematol."},{"key":"ref_20","first-page":"9","article-title":"Double hit diffuse large B-cell lymphomas: Diagnostic and therapeutic challenges","volume":"4","author":"Friedberg","year":"2015","journal-title":"Chin. Clin. Oncol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"e13046","DOI":"10.1097\/MD.0000000000013046","article-title":"Prognostic impact of germinal center B-cell-like and non-germinal center B-cell-like subtypes of bone marrow involvement in patients with diffuse large B-cell lymphoma treated with R-CHOP","volume":"97","author":"Cho","year":"2018","journal-title":"Medicine"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1200\/JCO.2016.68.2740","article-title":"Relapsed or refractory double-expressor and double-hit lymphomas have inferior progression-free survival after autologous stem-cell transplantation","volume":"35","author":"Herrera","year":"2017","journal-title":"J. Clin. Oncol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.3109\/10428194.2015.1096352","article-title":"Clinical significance of co-expression of MYC and BCL2 protein in aggressive B-cell lymphomas treated with a second line immunochemotherapy","volume":"57","author":"Miura","year":"2016","journal-title":"Leuk. Lymphoma"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"3121","DOI":"10.1200\/JCO.2005.05.1003","article-title":"Rituximab-CHOP versus CHOP alone or with maintenance rituximab in older patients with diffuse large B-cell lymphoma","volume":"24","author":"Habermann","year":"2006","journal-title":"J. Clin. Oncol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1056\/NEJMoa011795","article-title":"CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma","volume":"346","author":"Coiffier","year":"2002","journal-title":"New Engl. J. Med."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1819","DOI":"10.1200\/JCO.19.00014","article-title":"Late Relapses in Patients With Diffuse Large B-Cell Lymphoma Treated With Immunochemotherapy","volume":"37","author":"Wang","year":"2019","journal-title":"J. Clin. Oncol"},{"key":"ref_27","doi-asserted-by":"crossref","unstructured":"Tanimura, A., Hirai, R., Nakamura, M., Takeshita, M., Hagiwara, S., and Miwa, A. (2019). The Prognostic Impact of Dose-attenuated R-CHOP Therapy for Elderly Patients with Diffuse Large B-cell Lymphoma. Intern. Med.","DOI":"10.2169\/internalmedicine.0990-18"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"2354","DOI":"10.1182\/blood-2014-05-578963","article-title":"Impact of induction regimen and stem cell transplantation on outcomes in double-hit lymphoma: A multicenter retrospective analysis","volume":"124","author":"Petrich","year":"2014","journal-title":"Blood"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"919","DOI":"10.4143\/crt.2018.230","article-title":"Dose-dense rituximab-CHOP versus standard rituximab-CHOP in newly diagnosed Chinese patients with diffuse large B-cell lymphoma: A randomized, multicenter, open-label phase 3 trial","volume":"51","author":"Li","year":"2019","journal-title":"Cancer Res. Treat.: Off. J. Korean Cancer Assoc."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"4088","DOI":"10.1182\/blood-2019-123433","article-title":"Final Analysis of GOYA: A Randomized, Open-Label, Phase III Study of Obinutuzumab or Rituximab Plus CHOP in Patients with Previously Untreated Diffuse Large B-Cell Lymphoma","volume":"134","author":"Sehn","year":"2019","journal-title":"Blood"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"e609","DOI":"10.1016\/S2352-3026(18)30177-7","article-title":"Dose-adjusted EPOCH-R (etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin, and rituximab) in untreated aggressive diffuse large B-cell lymphoma with MYC rearrangement: A prospective, multicentre, single-arm phase 2 study","volume":"5","author":"Dunleavy","year":"2018","journal-title":"Lancet Haematol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1056\/NEJM199512073332305","article-title":"Autologous Bone Marrow Transplantation as Compared with Salvage Chemotherapy in Relapses of Chemotherapy-Sensitive Non-Hodgkin\u2019s Lymphoma","volume":"333","author":"Philip","year":"1995","journal-title":"N. Engl. J. Med."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1111\/bjh.15412","article-title":"How I manage patients with relapsed\/refractory diffuse large B cell lymphoma","volume":"182","author":"Gisselbrecht","year":"2018","journal-title":"Br. J. Haematol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"4184","DOI":"10.1200\/JCO.2010.28.1618","article-title":"Salvage regimens with autologous transplantation for relapsed large B-cell lymphoma in the rituximab era","volume":"28","author":"Gisselbrecht","year":"2010","journal-title":"J. Clin. Oncol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"81","DOI":"10.5500\/wjt.v5.i3.81","article-title":"Recent advances in post autologous transplantation maintenance therapies in B-cell non-Hodgkin lymphomas","volume":"5","author":"Epperla","year":"2015","journal-title":"World J. Transplant."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"1800","DOI":"10.1182\/blood-2017-03-769620","article-title":"Outcomes in refractory diffuse large B-cell lymphoma: Results from the international SCHOLAR-1 study","volume":"130","author":"Crump","year":"2017","journal-title":"Blood"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1182\/blood.V128.22.1115.1115","article-title":"A multi-institutional outcomes analysis of patients with relapsed or refractory diffuse large B-cell lymphoma treated with ibrutinib","volume":"128","author":"Winter","year":"2016","journal-title":"Blood"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"4127","DOI":"10.1158\/1078-0432.CCR-16-2818","article-title":"A phase 2\/3 multicenter, randomized, open-label study to compare the efficacy and safety of lenalidomide versus investigator\u2019s choice in patients with relapsed or refractory diffuse large B-cell lymphoma","volume":"23","author":"Czuczman","year":"2017","journal-title":"Clin. Cancer Res."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"e137","DOI":"10.1016\/S2352-3026(17)30016-9","article-title":"Lenalidomide maintenance in patients with relapsed diffuse large B-cell lymphoma who are not eligible for autologous stem cell transplantation: An open label, single-arm, multicentre phase 2 trial","volume":"4","author":"Ferreri","year":"2017","journal-title":"Lancet Haematol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"6069","DOI":"10.1182\/blood-2009-01-199679","article-title":"Differential efficacy of bortezomib plus chemotherapy within molecular subtypes of diffuse large B-cell lymphoma","volume":"113","author":"Dunleavy","year":"2009","journal-title":"Blood"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1182\/blood.V128.22.183.183","article-title":"A phase 1 study of nivolumab in combination with ipilimumab for relapsed or refractory hematologic malignancies (CheckMate 039)","volume":"128","author":"Ansell","year":"2016","journal-title":"Blood"},{"key":"ref_42","unstructured":"(2020, January 20). @NCICancerStats. Follicular Lymphoma - Cancer Stat Facts, Available online: https:\/\/seer.cancer.gov\/statfacts\/html\/follicular.html."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1126\/science.6093263","article-title":"Cloning of the chromosome breakpoint of neoplastic B cells with the t(14;18) chromosome translocation","volume":"226","author":"Tsujimoto","year":"1984","journal-title":"Science"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/0092-8674(89)90174-8","article-title":"BCL-2-Immunoglobulin transgenic mice demonstrate extended B cell survival and follicular lymphoproliferation","volume":"57","author":"McDonnell","year":"1989","journal-title":"Cell"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"5337","DOI":"10.1172\/JCI72415","article-title":"Germinal center reentries of BCL2-overexpressing B cells drive follicular lymphoma progression","volume":"124","author":"Sungalee","year":"2014","journal-title":"J. Clin. Investig."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"3165","DOI":"10.1182\/blood-2013-04-496893","article-title":"EZH2 mutations are frequent and represent an early event in follicular lymphoma","volume":"122","author":"Bodor","year":"2013","journal-title":"Blood"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"7527","DOI":"10.1200\/jco.2006.24.18_suppl.7527","article-title":"Initial therapeutic strategy in follicular lymphoma (FL): An analysis from the National LymphoCare Study (NLCS)","volume":"24","author":"Friedberg","year":"2016","journal-title":"J. Clin. Oncol."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1056\/NEJMoa1805104","article-title":"Rituximab plus Lenalidomide in Advanced Untreated Follicular Lymphoma","volume":"379","author":"Morschhauser","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_49","unstructured":"Fowler, N.H. (2016, January 18\u201322). How to Manage Early Relapsing\/Refractory Follicular Lymphoma. Proceedings of the Pan Pacific Lymphoma Conference, Koloa, Hawaii, USA."},{"key":"ref_50","first-page":"w14635","article-title":"Diagnosis and treatment of follicular lymphoma: An update","volume":"148","author":"Bargetzi","year":"2018","journal-title":"Swiss Med. Weekly"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/j.canrad.2017.09.003","article-title":"Radiotherapy of relapse-refractory follicular lymphoma","volume":"22","author":"Grignano","year":"2018","journal-title":"Cancer\/Radiother."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"2516","DOI":"10.1200\/JCO.2014.59.7534","article-title":"Early Relapse of Follicular Lymphoma After Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone Defines Patients at High Risk for Death: An Analysis From the National LymphoCare Study","volume":"33","author":"Casulo","year":"2015","journal-title":"J. Clin. Oncol."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1016\/j.bbmt.2017.12.771","article-title":"Autologous Transplantation in Follicular Lymphoma with Early Therapy Failure: A National LymphoCare Study and Center for International Blood and Marrow Transplant Research Analysis","volume":"24","author":"Casulo","year":"2018","journal-title":"Biol. Blood Marrow Transpl."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"1928","DOI":"10.1093\/annonc\/mdw282","article-title":"First-in-human phase I study of copanlisib (BAY 80-6946), an intravenous pan-class I phosphatidylinositol 3-kinase inhibitor, in patients with advanced solid tumors and non-Hodgkin\u2019s lymphomas","volume":"27","author":"Patnaik","year":"2016","journal-title":"Ann. Oncol."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1007\/s11899-018-0466-6","article-title":"Emerging EZH2 Inhibitors and Their Application in Lymphoma","volume":"13","author":"Lue","year":"2018","journal-title":"Curr. Hematol. Malig. Rep."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"1964","DOI":"10.1182\/blood-2018-11-880526","article-title":"Venetoclax plus R- or G-CHOP in non-Hodgkin lymphoma: Results from the CAVALLI phase 1b trial","volume":"133","author":"Zelenetz","year":"2019","journal-title":"Blood"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1177\/2040620716648566","article-title":"Bortezomib for the treatment of mantle cell lymphoma: An update","volume":"7","author":"Hambley","year":"2016","journal-title":"Ther. Adv. Hematol."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1038\/s41408-019-0209-5","article-title":"Patterns of survival in patients with recurrent mantle cell lymphoma in the modern era: Progressive shortening in response duration and survival after each relapse","volume":"9","author":"Kumar","year":"2019","journal-title":"Blood Cancer J."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"2687","DOI":"10.1182\/blood-2008-03-147025","article-title":"Long-term progression-free survival of mantle cell lymphoma after intensive front-line immunochemotherapy with in vivo-purged stem cell rescue: A nonrandomized phase 2 multicenter study by the Nordic Lymphoma Group","volume":"112","author":"Geisler","year":"2008","journal-title":"Blood"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1111\/j.1365-2141.2012.09174.x","article-title":"Nordic MCL2 trial update: Six-year follow-up after intensive immunochemotherapy for untreated mantle cell lymphoma followed by BEAM or BEAC + autologous stem-cell support: Still very long survival but late relapses do occur","volume":"158","author":"Geisler","year":"2012","journal-title":"Br. J. Haematol."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1016\/S0140-6736(16)00739-X","article-title":"Addition of high-dose cytarabine to immunochemotherapy before autologous stem-cell transplantation in patients aged 65 years or younger with mantle cell lymphoma (MCL Younger): A randomised, open-label, phase 3 trial of the European Mantle Cell Lymphoma Network","volume":"388","author":"Hermine","year":"2016","journal-title":"Lancet"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"1250","DOI":"10.1056\/NEJMoa1701769","article-title":"Rituximab after Autologous Stem-Cell Transplantation in Mantle-Cell Lymphoma","volume":"377","author":"Thieblemont","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1016\/S0140-6736(12)61763-2","article-title":"Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: An open-label, multicentre, randomised, phase 3 non-inferiority trial","volume":"381","author":"Rummel","year":"2013","journal-title":"Lancet"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"2944","DOI":"10.1182\/blood-2013-11-531327","article-title":"Randomized trial of bendamustine-rituximab or R-CHOP\/R-CVP in first-line treatment of indolent NHL or MCL: The BRIGHT study","volume":"123","author":"Flinn","year":"2014","journal-title":"Blood"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1056\/NEJMoa1412096","article-title":"Bortezomib-based therapy for newly diagnosed mantle-cell lymphoma","volume":"372","author":"Robak","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"e15","DOI":"10.1016\/S2352-3026(16)30185-5","article-title":"Rituximab, bendamustine, and low-dose cytarabine as induction therapy in elderly patients with mantle cell lymphoma: A multicentre, phase 2 trial from Fondazione Italiana Linfomi","volume":"4","author":"Visco","year":"2017","journal-title":"Lancet Haematol."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"1835","DOI":"10.1056\/NEJMoa1505237","article-title":"Lenalidomide plus Rituximab as Initial Treatment for Mantle-Cell Lymphoma","volume":"373","author":"Ruan","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1016\/S1470-2045(14)70311-0","article-title":"Combination of ibrutinib with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) for treatment-naive patients with CD20-positive B-cell non-Hodgkin lymphoma: A non-randomised, phase 1b study","volume":"15","author":"Younes","year":"2014","journal-title":"Lancet. Oncol."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"8003","DOI":"10.2147\/OTT.S155778","article-title":"Evaluating Acalabrutinib In The Treatment Of Mantle Cell Lymphoma: Design, Development, And Place In Therapy","volume":"12","author":"Girard","year":"2019","journal-title":"Onco Targets Ther."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1111\/j.1365-2141.2009.07626.x","article-title":"Lenalidomide oral monotherapy produces a high response rate in patients with relapsed or refractory mantle cell lymphoma","volume":"145","author":"Habermann","year":"2009","journal-title":"Br. J. Haematol"},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"2892","DOI":"10.1093\/annonc\/mdt366","article-title":"Long-term follow-up of lenalidomide in relapsed\/refractory mantle cell lymphoma: Subset analysis of the NHL-003 study","volume":"24","author":"Zinzani","year":"2013","journal-title":"Ann. Oncol"},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"3688","DOI":"10.1200\/JCO.2013.49.2835","article-title":"Single-agent lenalidomide in patients with mantle-cell lymphoma who relapsed or progressed after or were refractory to bortezomib: Phase II MCL-001 (EMERGE) study","volume":"31","author":"Goy","year":"2013","journal-title":"J. Clin. Oncol."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/S1470-2045(15)00559-8","article-title":"Lenalidomide versus investigator\u2019s choice in relapsed or refractory mantle cell lymphoma (MCL-002; SPRINT): A phase 2, randomised, multicentre trial","volume":"17","author":"Trneny","year":"2016","journal-title":"Lancet Oncol."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1200\/JCO.2005.03.108","article-title":"Phase II study of proteasome inhibitor bortezomib in relapsed or refractory B-cell non-Hodgkin\u2019s lymphoma","volume":"23","author":"Goy","year":"2005","journal-title":"J. Clin. Oncol."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1093\/annonc\/mdn656","article-title":"Bortezomib in patients with relapsed or refractory mantle cell lymphoma: Updated time-to-event analyses of the multicenter phase 2 PINNACLE study","volume":"20","author":"Goy","year":"2009","journal-title":"Ann. Oncol."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1016\/S0140-6736(15)00667-4","article-title":"Ibrutinib versus temsirolimus in patients with relapsed or refractory mantle-cell lymphoma: An international, randomised, open-label, phase 3 study","volume":"387","author":"Dreyling","year":"2016","journal-title":"Lancet"},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"1799","DOI":"10.1038\/s41375-018-0023-2","article-title":"Ibrutinib versus temsirolimus: 3-year follow-up of patients with previously treated mantle cell lymphoma from the phase 3, international, randomized, open-label RAY study","volume":"32","author":"Rule","year":"2018","journal-title":"Leukemia"},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"3822","DOI":"10.1200\/JCO.2008.20.7977","article-title":"Phase III study to evaluate temsirolimus compared with investigator\u2019s choice therapy for the treatment of relapsed or refractory mantle cell lymphoma","volume":"27","author":"Hess","year":"2009","journal-title":"J. Clin. Oncol."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1200\/JCO.2016.70.4320","article-title":"Phase I First-in-Human Study of Venetoclax in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma","volume":"35","author":"Davids","year":"2017","journal-title":"J. Clin. Oncol."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1038\/nrclinonc.2016.205","article-title":"The landscape of new drugs in lymphoma","volume":"14","author":"Younes","year":"2017","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1002\/ajh.25460","article-title":"Diffuse large B-cell lymphoma: 2019 update on diagnosis, risk stratification, and treatment","volume":"94","author":"Liu","year":"2019","journal-title":"Am. J. Hematol."},{"key":"ref_82","first-page":"1647","article-title":"Update on mantle cell lymphoma","volume":"132","author":"Maddocks","year":"2018","journal-title":"Blood J. Am. Soc. Hematol."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1002\/ajh.24937","article-title":"Follicular lymphoma: 2018 update on diagnosis and management","volume":"93","author":"Freedman","year":"2018","journal-title":"Am. J. Hematol."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.3904\/kjim.2015.006","article-title":"Assessment of bone marrow involvement in patients with lymphoma: Report on a consensus meeting of the Korean Society of Hematology Lymphoma Working Party","volume":"31","author":"Park","year":"2016","journal-title":"Korean J. Intern. Med."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/bs.ctdb.2016.01.009","article-title":"Hematopoietic Stem Cell and Its Bone Marrow Niche","volume":"118","author":"Yu","year":"2016","journal-title":"Current Topics in Developmental Biology"},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1007\/s00262-017-1992-0","article-title":"Bone marrow myeloid cells in regulation of multiple myeloma progression","volume":"66","author":"Herlihy","year":"2017","journal-title":"Cancer Immunol. Immunother."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"1911","DOI":"10.1148\/rg.2016160056","article-title":"MR Imaging of Pediatric Bone Marrow","volume":"36","author":"Chan","year":"2016","journal-title":"Radiographics"},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"288","DOI":"10.3389\/fonc.2018.00288","article-title":"Microenvironment Cell Contribution to Lymphoma Immunity","volume":"8","author":"Kumar","year":"2018","journal-title":"Front. Oncol."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1038\/nrd.2016.193","article-title":"Tumour-associated mesenchymal stem\/stromal cells: Emerging therapeutic targets","volume":"16","author":"Shi","year":"2017","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_90","doi-asserted-by":"crossref","unstructured":"Bareche, Y., Buisseret, L., Gruosso, T., Girard, E., Venet, D., Dupont, F., Desmedt, C., Larsimont, D., Park, M., and Rothe, F. (2019). Unraveling triple-negative breast cancer tumor microenvironment heterogeneity: Towards an optimized treatment approach. J. Natl. Cancer Inst.","DOI":"10.1093\/jnci\/djz208"},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1016\/j.blre.2018.04.006","article-title":"Myeloid-derived suppressor cells in lymphoma: The good, the bad and the ugly","volume":"32","author":"Betsch","year":"2018","journal-title":"Blood Rev."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1111\/ijlh.12203","article-title":"CD14(+) HLA-DR low\/(-) monocytes as indicator of disease aggressiveness in B-cell non-Hodgkin lymphoma","volume":"36","author":"Khalifa","year":"2014","journal-title":"Int J. Lab. Hematol"},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1200\/JCO.2007.12.8298","article-title":"High numbers of tumor-associated macrophages have an adverse prognostic value that can be circumvented by rituximab in patients with follicular lymphoma enrolled onto the GELA-GOELAMS FL-2000 trial","volume":"26","author":"Canioni","year":"2008","journal-title":"J. Clin. Oncol."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"116","DOI":"10.3324\/haematol.2017.177162","article-title":"Inhibition of focal adhesion kinase overcomes resistance of mantle cell lymphoma to ibrutinib in the bone marrow microenvironment","volume":"103","author":"Rudelius","year":"2018","journal-title":"Haematologica"},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1158\/1078-0432.CCR-15-0987","article-title":"ROS-Induced CXCR4 Signaling Regulates Mantle Cell Lymphoma (MCL) Cell Survival and Drug Resistance in the Bone Marrow Microenvironment via Autophagy","volume":"22","author":"Chen","year":"2016","journal-title":"Clin. Cancer Res."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1038\/leu.2008.266","article-title":"Lymphoma cell adhesion-induced expression of B cell-activating factor of the TNF family in bone marrow stromal cells protects non-Hodgkin\u2019s B lymphoma cells from apoptosis","volume":"23","author":"Lwin","year":"2009","journal-title":"Leukemia"},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1159\/000488385","article-title":"Highly Tumorigenic Diffuse Large B Cell Lymphoma Cells Are Produced by Coculture with Stromal Cells","volume":"139","author":"Lin","year":"2018","journal-title":"Acta Haematol"},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1182\/blood-2014-04-568188","article-title":"Jun-regulated genes promote interaction of diffuse large B-cell lymphoma with the microenvironment","volume":"125","author":"Blonska","year":"2015","journal-title":"Blood"},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"1921","DOI":"10.3109\/10428194.2015.1121261","article-title":"Activation of the polycomb repressive complex pathway in the bone marrow resident cells of diffuse large B-cell lymphoma patients","volume":"57","author":"Oh","year":"2016","journal-title":"Leuk Lymphoma"},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"2957","DOI":"10.1182\/blood-2006-04-018218","article-title":"High numbers of tumor-infiltrating FOXP3-positive regulatory T cells are associated with improved overall survival in follicular lymphoma","volume":"108","author":"Carreras","year":"2006","journal-title":"Blood"},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1038\/ni904","article-title":"Foxp3 programs the development and function of CD4+CD25+ regulatory T cells","volume":"4","author":"Fontenot","year":"2003","journal-title":"Nat. Immunol."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"3639","DOI":"10.1182\/blood-2005-08-3376","article-title":"Intratumoral CD4+CD25+ regulatory T-cell-mediated suppression of infiltrating CD4+ T cells in B-cell non-Hodgkin lymphoma","volume":"107","author":"Yang","year":"2006","journal-title":"Blood"},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"193","DOI":"10.3324\/haematol.11702","article-title":"Correlation of high numbers of intratumoral FOXP3+ regulatory T cells with improved survival in germinal center-like diffuse large B-cell lymphoma, follicular lymphoma and classical Hodgkin\u2019s lymphoma","volume":"93","author":"Tzankov","year":"2008","journal-title":"haematologica"},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"e2016045","DOI":"10.4084\/mjhid.2016.045","article-title":"The role of autologous and allogeneic stem cell transplantation in follicular lymphoma in the new drugs era","volume":"8","author":"Maura","year":"2016","journal-title":"Mediterr. J. Hematol. Infect. Dis."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"4417","DOI":"10.1002\/cncr.32464","article-title":"Upfront autologous hematopoietic stem cell transplantation consolidation for patients with aggressive B-cell lymphomas in first remission in the rituximab era: A systematic review and meta-analysis","volume":"125","author":"Epperla","year":"2019","journal-title":"Cancer"},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"1863","DOI":"10.1016\/j.bbmt.2015.07.032","article-title":"Indications for Autologous and Allogeneic Hematopoietic Cell Transplantation: Guidelines from the American Society for Blood and Marrow Transplantation","volume":"21","author":"Majhail","year":"2015","journal-title":"Biol. Blood Marrow Transpl."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"1661","DOI":"10.1182\/bloodadvances.2019000102","article-title":"Postrelapse survival in diffuse large B-cell lymphoma after therapy failure following autologous transplantation","volume":"3","author":"Epperla","year":"2019","journal-title":"Blood Adv."},{"key":"ref_108","doi-asserted-by":"crossref","unstructured":"Gonzlez-Barca, E., Boumendil, A., and Blaise, D. (2019). Outcome in patients with diffuse large B-cell lymphoma who relapse after autologous stem cell transplantation and receive active therapy. A retrospective analysis of the Lymphoma Working Party of the European Society for Blood and Marrow Transplantation (EBMT). Bone Marrow Transplant.","DOI":"10.1038\/s41409-019-0650-x"},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1046\/j.1365-2141.2003.04140.x","article-title":"Outcome of autologous transplantation for mantle cell lymphoma: A study by the European Blood and Bone Marrow Transplant and Autologous Blood and Marrow Transplant Registries","volume":"120","author":"Vandenberghe","year":"2003","journal-title":"Br. J. Haematol."},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1111\/bjh.14046","article-title":"Allogeneic transplantation provides durable remission in a subset of DLBCL patients relapsing after autologous transplantation","volume":"174","author":"Fenske","year":"2016","journal-title":"Br. J. Haematol"},{"key":"ref_111","first-page":"938","article-title":"Reduced-intensity transplantation for lymphomas using haploidentical related donors vs. HLA-matched unrelated donors","volume":"127","author":"Kanate","year":"2016","journal-title":"Blood J. Am. Soc. Hematol."},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"3141","DOI":"10.1200\/JCO.2015.66.3476","article-title":"Reduced-intensity transplantation for lymphomas using haploidentical related donors versus HLA-matched sibling donors: A Center for International Blood and Marrow Transplant Research analysis","volume":"34","author":"Ghosh","year":"2016","journal-title":"J. Clin. Oncol."},{"key":"ref_113","doi-asserted-by":"crossref","unstructured":"Lemieux, C., Ahmad, I., Bambace, N.M., Bernard, L., Cohen, S., Delisle, J.S., Fleury, I., Kiss, T., Mollica, L., and Roy, D.C. (2019). Evaluation of the Impact of Autologous Hematopoietic Stem Cell Transplantation on the Quality of Life of Older Patients with Lymphoma. Biol. Blood Marrow Transpl.","DOI":"10.1016\/j.bbmt.2019.09.007"},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1038\/s41409-019-0624-z","article-title":"Death after hematopoietic stem cell transplantation: Changes over calendar year time, infections and associated factors","volume":"55","author":"Tridello","year":"2020","journal-title":"Bone Marrow Transplant."},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1007\/s00432-018-2633-5","article-title":"Allogeneic haematopoietic cell transplantation offers the chance of cure for patients with transformed follicular lymphoma","volume":"144","author":"Heinzelmann","year":"2018","journal-title":"J. Cancer Res. Clin. Oncol."},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"5210459","DOI":"10.1155\/2017\/5210459","article-title":"Genetically Modified T-Cell-Based Adoptive Immunotherapy in Hematological Malignancies","volume":"2017","author":"Ye","year":"2017","journal-title":"J. Immunol. Res."},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"2245","DOI":"10.1016\/j.ymthe.2017.07.004","article-title":"Long-Duration Complete Remissions of Diffuse Large B Cell Lymphoma after Anti-CD19 Chimeric Antigen Receptor T Cell Therapy","volume":"25","author":"Kochenderfer","year":"2017","journal-title":"Mol. Ther."},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1186\/2162-3619-1-36","article-title":"CD19: A biomarker for B cell development, lymphoma diagnosis and therapy","volume":"1","author":"Wang","year":"2012","journal-title":"Exp. Hematol. Oncol."},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"2257","DOI":"10.1172\/JCI45851","article-title":"CD19 is a major B cell receptor\u2013independent activator of MYC-driven B-lymphomagenesis","volume":"122","author":"Chung","year":"2012","journal-title":"J. Clin. Investig."},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"385","DOI":"10.3109\/10428199509059636","article-title":"CD19 antigen in leukemia and lymphoma diagnosis and immunotherapy","volume":"18","author":"Scheuermann","year":"1995","journal-title":"Leuk. Lymphoma"},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1007\/s11095-018-2436-z","article-title":"Chimeric antigen receptor T-cells (CAR T-cells) for cancer immunotherapy\u2013moving target for industry?","volume":"35","author":"Salmikangas","year":"2018","journal-title":"Pharm. Res."},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"8516","DOI":"10.1200\/jco.2015.33.15_suppl.8516","article-title":"Phase IIa trial of chimeric antigen receptor modified T cells directed against CD19 (CTL019) in patients with relapsed or refractory CD19+ lymphomas","volume":"33","author":"Schuster","year":"2015","journal-title":"J. Clin. Oncol."},{"key":"ref_123","doi-asserted-by":"crossref","unstructured":"Wang, M. (2019, January 7\u201310). KTE-X19, an Anti-CD19 Chimeric Antigen Receptor (CAR) T Cell Therapy, in Patients (Pts) With Relapsed\/Refractory (R\/R) Mantle Cell Lymphoma (MCL): Results of the Phase 2 ZUMA-2 Study. Proceedings of the 61st Annual Meeting and Exposition, Orlando, FL, USA.","DOI":"10.1182\/blood-2019-126064"},{"key":"ref_124","first-page":"581","article-title":"High durable CR rates in R\/R aggressive B-NHL treated with JCAR017 (lisocabtagene maraleucel; liso-cel)(TRANSCEND NHL 001): Defined composition CD19-directed CAR T cell product allows for dose finding and definition of pivotal cohort","volume":"130","author":"Abramson","year":"2017","journal-title":"Blood"},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"2767","DOI":"10.1038\/s41375-019-0615-5","article-title":"CD19 chimeric antigen receptor-T cells in B-cell leukemia and lymphoma: Current status and perspectives","volume":"33","author":"Mohty","year":"2019","journal-title":"Leukemia"},{"key":"ref_126","doi-asserted-by":"crossref","unstructured":"Michallet, M., Dreger, P., Sobh, M., Koster, L., Hoek, J., Boumendil, A., Scheid, C., Fox, C.P., Wulf, G., and Kruger, W. (2019). Ibrutinib as a salvage therapy after allogeneic HCT for chronic lymphocytic leukemia. Bone Marrow Transpl.","DOI":"10.1038\/s41409-019-0742-7"},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.clml.2018.10.005","article-title":"Ibrutinib Dose Adherence and Therapeutic Efficacy in Non-Hodgkin Lymphoma: A Single-Center Experience","volume":"19","author":"Williams","year":"2019","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"6860","DOI":"10.1002\/cam4.2565","article-title":"Clinical outcomes for ibrutinib in relapsed or refractory mantle cell lymphoma in real-world experience","volume":"8","author":"Jeon","year":"2019","journal-title":"Cancer Med."},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"3248","DOI":"10.1182\/bloodadvances.2019000703","article-title":"Rational design of a trimeric APRIL-based CAR-binding domain enables efficient targeting of multiple myeloma","volume":"3","author":"Schmidts","year":"2019","journal-title":"Blood Adv."},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.critrevonc.2014.08.003","article-title":"Bispecific antibody platforms for cancer immunotherapy","volume":"92","author":"Lameris","year":"2014","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.ctrv.2018.04.002","article-title":"Bispecific antibodies in haematological malignancies","volume":"65","author":"Viardot","year":"2018","journal-title":"Cancer Treat. Rev."},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1016\/j.bbrc.2018.12.175","article-title":"CD47\/SIRP\u03b1 blocking enhances CD19\/CD3-bispecific T cell engager antibody-mediated lysis of B cell malignancies","volume":"509","author":"Xu","year":"2019","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1182\/blood-2019-123742","article-title":"Mosunetuzumab Induces Complete Remissions in Poor Prognosis Non-Hodgkin Lymphoma Patients, Including Those Who Are Resistant to or Relapsing After Chimeric Antigen Receptor T-Cell (CAR-T) Therapies, and Is Active in Treatment through Multiple Lines","volume":"134","author":"Schuster","year":"2019","journal-title":"Blood"},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1158\/2326-6066.CIR-14-0040","article-title":"In vitro characterization of the anti-PD-1 antibody nivolumab, BMS-936558, and in vivo toxicology in non-human primates","volume":"2","author":"Wang","year":"2014","journal-title":"Cancer Immunol. Res."},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1111\/imr.12233","article-title":"Targeting the bone marrow microenvironment in multiple myeloma","volume":"263","author":"Kawano","year":"2015","journal-title":"Immunol. Rev."},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1016\/S0960-9822(02)00506-7","article-title":"Lymphocyte activation: T-cell regulation by CTLA-4","volume":"6","author":"Linsley","year":"1996","journal-title":"Curr. Biol."},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"2535","DOI":"10.1080\/10428194.2018.1434886","article-title":"Targeting the bone marrow microenvironment in acute leukemia","volume":"59","author":"Karantanou","year":"2018","journal-title":"Leuk Lymphoma"},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1016\/j.bbamcr.2015.08.015","article-title":"Advances in understanding the acute lymphoblastic leukemia bone marrow microenvironment: From biology to therapeutic targeting","volume":"1863","author":"Chiarini","year":"2016","journal-title":"Biochim. Biophys. Acta"},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1111\/j.1365-2141.2008.07093.x","article-title":"Hypoxia inducible factor-alpha activation in lymphoma and relationship to the thioredoxin family","volume":"141","author":"Evens","year":"2008","journal-title":"Br. J. Haematol."},{"key":"ref_140","doi-asserted-by":"crossref","first-page":"96474","DOI":"10.18632\/oncotarget.22103","article-title":"Targeting the leukemic bone marrow microenvironment","volume":"8","author":"Neumann","year":"2017","journal-title":"Oncotarget"},{"key":"ref_141","doi-asserted-by":"crossref","first-page":"5597","DOI":"10.18632\/oncotarget.3343","article-title":"Dysregulated CXCR4 expression promotes lymphoma cell survival and independently predicts disease progression in germinal center B-cell-like diffuse large B-cell lymphoma","volume":"6","author":"Chen","year":"2015","journal-title":"Oncotarget"},{"key":"ref_142","doi-asserted-by":"crossref","first-page":"271","DOI":"10.2174\/157339406777934717","article-title":"Cancer therapy-induced residual bone marrow injury: Mechanisms of induction and implication for therapy","volume":"2","author":"Wang","year":"2006","journal-title":"Curr. Cancer Ther. Rev."},{"key":"ref_143","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1080\/10245332.2018.1486064","article-title":"Roles of the bone marrow niche in hematopoiesis, leukemogenesis, and chemotherapy resistance in acute myeloid leukemia","volume":"23","author":"Wang","year":"2018","journal-title":"Hematology"}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/21\/3\/904\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T08:53:15Z","timestamp":1760172795000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/21\/3\/904"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,1,30]]},"references-count":143,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2020,2]]}},"alternative-id":["ijms21030904"],"URL":"https:\/\/doi.org\/10.3390\/ijms21030904","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,1,30]]}}}